“ROLE OF SERUM ADENOSINE DEAMINASE ACTIVITY IN ASSESSING PSORIASIS SEVERITY: A HOSPITAL-BASED CROSS SECTIONAL STUDY”
Main Article Content
Keywords
Serum adenosine deaminase, Psoriasis, PASI, Inflammation, Biomarker
Abstract
BACKGROUND: Psoriasis is a common, chronic, inflammatory and proliferative condition of the skin, often associated with systemic manifestations in multiple organ systems. World Health Organization (WHO) considered psoriasis as a global health problem. In India the prevalence of psoriasis ranges from 0.4-2.8%. The reported prevalence of psoriasis in countries ranges between 0.09% and 11.4% making psoriasis a serious global problem. PASI is recommended as the current gold standard for assessing the severity of psoriasis and for clinical trials.
AIM: To assess the role of serum adenosine deaminase (ADA) activity in predicting disease severity in psoriasis patients.
MATERIAL & METHODS: This hospital-based cross-sectional study was conducted in the Department of Biochemistry and Department of Physiology, over a period of 12 months. A total of 150 newly diagnosed psoriasis patients attending OPD and IPD were included. Disease severity was scored according to the Psoriasis Area and Severity Index (PASI).
RESULTS: The majority of patients were males (70%) with mean age 37.6 ± 10.3 years. Mean serum ADA level was 24.1 ± 5.2 U/L, significantly higher than reference values (p<0.0001). ADA levels increased with severity: 20.8 ± 2.1 U/L in mild, 28.6 ± 1.4 U/L in moderate, and 31.7 ± 4.2 U/L in severe psoriasis. ADA showed strong positive correlation with PASI score (r=0.978, p<0.0001).
CONCLUSION: Serum adenosine deaminase activity demonstrates a significant positive correlation with disease severity in psoriasis. It may serve as a simple, reliable biomarker for assessing disease severity and monitoring therapeutic outcomes.
References
2. Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205–12.
3. Dogra S, Yadav S. Psoriasis in India: Prevalence and pattern. Indian J Dermatol Venereol Leprol. 2010;76(6):595–601.
4. Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: A review. JAMA. 2020;323(19):1945–60.
5. Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, Gelfand JM. Psoriasis and comorbid diseases: Epidemiology. J Am Acad Dermatol. 2017;76(3):377–90.
6. Tsoi LC, Spain SL, Knight J, Ellinghaus E, Stuart PE, Capon F, et al. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet. 2012;44(12):1341–8.
7. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496–509.
8. Lowes MA, Suárez-Fariñas M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol. 2014;32:227–55.
9. Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983–94.
10. Puzenat E, Bronsard V, Prey S, Gourraud PA, Aractingi S, Aubin F, et al. What are the best outcome measures for assessing plaque psoriasis severity? A systematic review. J Eur Acad Dermatol Venereol. 2010;24(Suppl 2):10–6.
11. Fredriksson T, Pettersson U. Severe psoriasis—oral therapy with a new retinoid. Dermatologica. 1978;157(4):238–44.
12. Sullivan KE, Cutilli J, Piliero LM, Ghavimi-Alagha D, Starr SE, Campbell DE, et al. Measurement of adenosine deaminase activity in lymphocytes. Clin Diagn Lab Immunol. 1999;6(1):42–8.
13. Ungerer JP, Oosthuizen HM, Bissbort SH, Vermaak WJ. Serum adenosine deaminase: isoenzymes and diagnostic application. Clin Chem. 1992;38(7):1322–6.
14. Piras MA, Gakis C, Budroni M, Andreoni G. Adenosine deaminase activity in pleural effusions: an aid to differential diagnosis. BMJ. 1978;2(6154):1751–2.
15. Koseoglu V, Ersöz C, Kocamaz H, Demirkan N, Ozdemir S. Serum adenosine deaminase activity in autoimmune diseases. Clin Biochem. 1999;32(6):409–13.
16. Aggarwal R, Singh R, Aggarwal M. Adenosine deaminase activity in psoriasis. Indian J Dermatol Venereol Leprol. 2003;69(3):183–5.
17. Bhatnagar S, Gupta S, Kumar S. Adenosine deaminase activity in psoriasis patients. Indian J Clin Biochem. 2007;22(2):70–2.
18. Uyar B, Okçu Heper A, Serarslan G, Soyuer U, Yildirim H. Serum adenosine deaminase activity in patients with psoriasis and its relation to severity. Clin Exp Dermatol. 2007;32(5):489–92.
19. Dogan B, Caliskan D, Tekin NS, Atakan N. Adenosine deaminase activity in psoriasis vulgaris and changes with treatment. Dermatology. 2008;217(1):23–7
20. Uyar B, Okçu Heper A, Serarslan G, Soyuer U, Yildirim H. Serum adenosine deaminase activity in patients with psoriasis and its relation to severity of disease. Clin Exp Dermatol. 2007;32(5):489–92.
21. Dogan B, Caliskan D, Tekin NS, Atakan N. Adenosine deaminase activity in psoriasis vulgaris and changes with treatment. Dermatology. 2008;217(1):23–7.
22. Antonioli L, Fornai M, Blandizzi C, Pacher P, Haskó G. Adenosine signaling and the immune system: when a lot could be too much. Immunol Lett. 2019;205:9–15.
23. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496–509.
24. Lowes MA, Suárez-Fariñas M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol. 2014;32:227–55.
25. Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983–94.
26. Krueger JG, Bowcock A. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis. 2005;64 Suppl 2:ii30–6.
27. Shukla A, Kaur J, Srivastava A. Serum adenosine deaminase activity as a biomarker in monitoring psoriasis treatment response. Int J Dermatol. 2016;55(11):1271–6.
28. Caliskan D, Dogan B, Tekin NS. Serum adenosine deaminase activity and treatment monitoring in psoriasis. J Dermatol Treat. 2009;20(5):293–6.
29. Puzenat E, Bronsard V, Prey S, Gourraud PA, Aractingi S, Aubin F, et al. What are the best outcome measures for assessing plaque psoriasis severity? J Eur Acad Dermatol Venereol. 2010;24 Suppl 2:10–6.
30. Johnston A, Guzman AM, Swindell WR, Wang F, Xing X, Nair RP, et al. Early tissue responses in psoriasis to TNF-α blockade. J Invest Dermatol. 2014;134(5):1348–60.
31. Armstrong AW, Mehta MD, Schupp CW, Gondo GC, Bell SJ, Griffiths CEM. Psoriasis prevalence in adults: a systematic review. JAMA Dermatol. 2013;149(7):801–6.
33. Gakis C. Adenosine deaminase and chronic liver disease. Clin Biochem. 2009;42(1-2):2–8.
34. Zavialov AV, Gracia E, Glaichenhaus N, Franco R, Zavialov AV. Human adenosine deaminase 2: a growth factor and modulator of monocyte differentiation. Blood. 2010;115(13):2708–15.
35. University of British Columbia. Post-inflammatory lentiginous hyperpigmentation in psoriasis: exploratory retrospective study. Oral Abstracts, Dermatology Division; 2024. Available from: https://med-fom-derm.sites.olt.ubc.ca/files/2024/08/6.-Oral-abstracts.pdf
36. Ahad T. Phototherapy: practical management and guidelines in Canadian dermatology. Can Dermatol Today. 2024;6(1). Available from: https://canadiandermatologytoday.com/ article/view/6-1-Ahad
37. Canadian Psoriasis Network. PsoSerious 2024: A national report on psoriatic disease care in Canada. 2024. Available from: https://canadianpsoriasis.ca/en/resources/reports/psoserious-2024
38. Gooderham MJ, et al. Phase 3 results from an innovative trial design of treating plaque psoriasis involving difficult-to-treat, high-impact sites with icotrokinra, a targeted oral peptide that selectively inhibits the IL-23–receptor. Presented at the 2025 Society for Investigative Dermatology (Abstract #LB1142), May 2025. Available from: Corporate media release by Johnson & Johnson media center.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Dr. Kedar Prasad Yadav
Associate Professor1, Department of Biochemistry, Autonomous State Medical College, Hardoi, Uttar Pradesh, India.
Dr. Divya Jaiswal
Associate professor and Head2, Department of Physiology, A.S.J.S.A.T.D.S. Medical College Fatehpur, India
Dr. Sankha Simlai
Professor3, Department of Biochemistry, Prasad Institute of Medical Sciences, Uttar Pradesh, India.
Dr. Nashra Afaq
Assistant Professor4, Department of Microbiology and Central Research Laboratory, Rama Medical College Hospital and Research Centre, Uttar Pradesh, India.
Dr. Shaheen Bhat
Associate Professor5, Department of Microbiology, SMS & R, Sharda hospital,Greater Noida, India.
Dr. Ayesha Nazar
Assistant Professor6, Department of Microbiology, SMS & R, Sharda hospital,Greater Noida, India.
Dr. Furquan Alam
Professor7*, Department of Biochemistry, Integral Institute of Medical Sciences and Research, Integral University, Lucknow, Uttar Pradesh, India.